Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic Targets in Nonalcoholic Fatty Liver Disease
William P. Esler, Kendra K. Bence
Cellular and Molecular Gastroenterology and Hepatology (2019) Vol. 8, Iss. 2, pp. 247-267
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Yana Geng, Klaas Nico Faber, Vincent E. de Meijer, et al.
Hepatology International (2021) Vol. 15, Iss. 1, pp. 21-35
Open Access | Times Cited: 244
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 235
Therapeutic Landscape for NAFLD in 2020
Brent A. Neuschwander‐Tetri
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1984-1998.e3
Closed Access | Times Cited: 168
Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
Douglas G. Mashek
Molecular Metabolism (2020) Vol. 50, pp. 101115-101115
Open Access | Times Cited: 163
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1836-1848
Closed Access | Times Cited: 155
Metabolic drivers of non-alcoholic fatty liver disease
Kendra K. Bence, Morris J. Birnbaum
Molecular Metabolism (2020) Vol. 50, pp. 101143-101143
Open Access | Times Cited: 153
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
Delilah Hendriks, Jos F. Brouwers, Karien M. Hamer, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 11, pp. 1567-1581
Open Access | Times Cited: 99
Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis
Hangyu Li, Siyu Huang, Dan-Dan Zhou, et al.
Journal of Advanced Research (2023) Vol. 52, pp. 59-72
Open Access | Times Cited: 52
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
William P. Esler, David E. Cohen
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 362-377
Open Access | Times Cited: 40
Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
Karli R. LeFort, Wiramon Rungratanawanich, Byoung‐Joon Song
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 31
Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability
Stanisław Deja, Justin A. Fletcher, Chai-Wan Kim, et al.
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 1088-1104.e12
Open Access | Times Cited: 17
Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors
Leyuan Chen, Yuqing Duan, Huiqiang Wei, et al.
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 10, pp. 917-930
Closed Access | Times Cited: 112
Evolving Role for Pharmacotherapy in NAFLD/NASH
Suzanna Attia, Samir Softic, Marialena Mouzaki
Clinical and Translational Science (2020) Vol. 14, Iss. 1, pp. 11-19
Open Access | Times Cited: 109
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Rohit Loomba, Erin Morgan, Lynnetta M. Watts, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 9, pp. 829-838
Closed Access | Times Cited: 89
Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression
Kuo Du, Satish K. Chitneni, Ayako Suzuki, et al.
Cellular and Molecular Gastroenterology and Hepatology (2019) Vol. 10, Iss. 1, pp. 1-21
Open Access | Times Cited: 75
Serine catabolism generates liver NADPH and supports hepatic lipogenesis
Zhaoyue Zhang, Tara TeSlaa, Xincheng Xu, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1608-1620
Open Access | Times Cited: 72
Tracing insights into de novo lipogenesis in liver and adipose tissues
Martina Wallace, Christian M. Metallo
Seminars in Cell and Developmental Biology (2020) Vol. 108, pp. 65-71
Closed Access | Times Cited: 69
Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation
Ying Wang, Chaojie Chen, Jiajun Chen, et al.
Redox Biology (2022) Vol. 52, pp. 102322-102322
Open Access | Times Cited: 64
Integrins as a drug target in liver fibrosis
S. Rahman, James A. Roper, Jane I. Grove, et al.
Liver International (2022) Vol. 42, Iss. 3, pp. 507-521
Open Access | Times Cited: 50
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Majid Mufaqam Syed‐Abdul
Metabolites (2023) Vol. 14, Iss. 1, pp. 12-12
Open Access | Times Cited: 26
Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology
Neeta B. Amin, Aditi R. Saxena, Veena Somayaji, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 1, pp. 55-70
Open Access | Times Cited: 24
Natural alkaloid and polyphenol compounds targeting lipid metabolism: Treatment implications in metabolic diseases
Can Cheng, Zhenzhen Li, Xu Zhao, et al.
European Journal of Pharmacology (2020) Vol. 870, pp. 172922-172922
Closed Access | Times Cited: 61
Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
Clarissa Berardo, Laura Giuseppina Di Pasqua, Marta Cagna, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9646-9646
Open Access | Times Cited: 60
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 13, pp. 1637-1649
Closed Access | Times Cited: 52
The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis
Yu An, Shiuhwei Chen, Yingfeng Deng, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 2, pp. 387-399
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top